KalVista Pharmaceuticals, Inc. (FRA:4XC1)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.24B +152.3% |
| Revenue (ttm) | 99.29M |
| Net Income | -117.90M |
| EPS | -2.17 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 22.73 |
| Previous Close | 23.13 |
| Day's Range | 22.73 - 22.73 |
| 52-Week Range | 9.00 - 23.26 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 9, 2026 |
About KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmace... [Read more]
News
Chiesi Group completes KalVista acquisition
Chiesi Group announced the completion of its acquisition of KalVista (KALV) Pharmaceuticals. KalVista is now part of Chiesi Group and will contribute to the growth of the Rare Diseases business…
Chiesi Group Completes Acquisition of KalVista Pharmaceuticals
PARMA, Italy & FRAMINGHAM, Mass.--(BUSINESS WIRE)--Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, today announced the completion of its acquis...
KalVista presents new data on injectable on-demand treatment in children
KalVista (KALV) Pharmaceuticals announced new data highlighting the burden of injectable on-demand treatment in children aged 2-11 with hereditary angioedema presented at ISPOR 2026 and the Eastern Al...
KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children ag...
KalVista Pharmaceuticals Quarterly report: Q1 2026
KalVista Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 14, 2026.
KalVista downgraded to Hold from Buy at Stifel
Stifel analyst Paul Matteis downgraded KalVista (KALV) to Hold from Buy after the company entered into a merger agreement to be acquired by Chiesi Group at a price of $27…
KalVista downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein downgraded KalVista (KALV) to Neutral from Buy with a price target of $27, down from $37, after the company entered into a merger agreement to…
KalVista downgraded to Hold from Buy at Needham
Needham downgraded KalVista (KALV) to Hold from Buy after Chiesi announced an agreement to acquire KalVista for $27 per share in cash.
KalVista downgraded to Hold from Buy at JonesResearch
JonesResearch downgraded KalVista (KALV) to Hold from Buy with a $27 price target after Chiesi announced an agreement to acquire KalVista for $27 per share in cash, implying an equity…
KalVista downgraded to Market Perform from Outperform at Leerink
Leerink downgraded KalVista (KALV) to Market Perform from Outperform with a $27 price target after Chiesi Group agreed to acquire all outstanding shares of KalVista for $27 per share in…
KalVista downgraded to Market Perform from Outperform at Citizens
Citizens downgraded KalVista (KALV) to Market Perform from Outperform after Chiesi Group agreed to acquire all outstanding shares of KalVista for $27 per share in cash.
KalVista moved to No Rating at BofA
BofA moved to No Rating on KalVista (KALV) Pharmaceuticals after the company agreed to be acquired by Italian company Chiesi Group for $27 per share. KalVista is no longer trading…
Chiesi Group to acquire KalVista for $27.00 per share in cash
Chiesi Group and KalVista (KALV) Pharmaceuticals entered into a definitive agreement under which Chiesi will acquire KalVista. The Transaction was unanimously approved by both Chiesi’s and KalVista’s ...
Italian drugmaker Chiesi to buy KalVista for $1.9 billion
Italy's Chiesi has agreed to buy KalVista Pharmaceuticals for about $1.9 billion, the company said on Wednesday, as it looks to grow its rare disease drug portfolio.
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio
PARMA, Italy & FRAMINGHAM, Mass.--(BUSINESS WIRE)--Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc. (“KalVist...
Italian pharma group Chiesi to buy US peer KalVista for $1.9 billion
Italian pharma company Chiesi Group will buy U.S.-listed KalVista Pharmaceuticals in an all-cash deal valued at about $1.9 billion, the two companies said in a joint statement on Wednesday.
KalVista Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference
EKTERLY's launch has seen rapid uptake in the US, Germany, and Japan, with strong physician and patient satisfaction and over 20% market penetration. Formulary access is expanding, pediatric and short-term prophylaxis opportunities are advancing, and the company is well-funded to reach profitability.
KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at the 25th Annual Needham ...
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Compensation Committee of KalVista's Board of Directors granted five ne...
KalVista announces interim Phase 3 data from KONFIDENT-KID trial of EKTERLY
KalVista (KALV) Pharmaceuticals announced new interim results from its KONFIDENT-KID clinical trial evaluating EKTERLY for the on-demand treatment of hereditary angioedema attacks in children ages 2-1...
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new interim results from its KONFIDENT-KID clinical trial evaluating EKTERLY® (se...
KalVista price target lowered to $28 from $29 at Citizens
Citizens analyst Jonathan Wolleben lowered the firm’s price target on KalVista (KALV) to $28 from $29 and keeps an Outperform rating on the shares. KalVista’s Q4 results aligned with the…
KalVista price target raised to $42 from $39 at Stifel
Stifel analyst Paul Matteis raised the firm’s price target on KalVista (KALV) to $42 from $39 and keeps a Buy rating on the shares. Rapid growth in Ekterly starts “continues…
KalVista Pharmaceuticals Transcript: Transition period
EKTERLY's U.S. launch drove $49.1M in eight-month revenue, with rapid adoption and strong patient and physician satisfaction. Global expansion is underway, and EKTERLY is now a first-line therapy for adolescents, supporting long-term growth.
KalVista Pharmaceuticals Earnings release: Transition period
KalVista Pharmaceuticals released its earnings on March 25, 2026, summarizing the period's financial results.